Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 21, which means every article in Clinical Investigation has got 21 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

  2020 2019 2018 2017 2016

Year wise published articles

28 19 22 19 2

Year wise citations received

222 233 233 230 181
Journal total citations count 1936
Journal impact factor 6.44
Journal 5 years impact factor 12.56
Journal cite score 10.78
Journal h-index 21
Journal h-index since 2016 18
Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/
{Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3
  • Freidlin B, Korn EL (2014) Biomarker enrichment strategies: matching trial design to biomarker credentials. Nature reviews Clinical oncology 11: 81-90. View at Publisher | View at Google Scholar | View at Indexing
  • 田平武, 松本信英, 金海峰. シンポジウム 32―3 神経疾患に対する抗体療法 アルツハイマー病に対する抗体療法. 臨床神経学. 2011;51(11):1160-1. View at Publisher | View at Google Scholar | View at Indexing
  • 田平武. Aβ を標的とする Alzheimer 病の免疫療法. 神経治療学. 2016;33(3):415-9. View at Publisher | View at Google Scholar | View at Indexing
  • Atkinson AC (2014) Selecting a biased-coin design. Statistical Science 29: 144-63.

    View at Publisher | View at Google Scholar
  • 周军, 夏春, 沈勤, 印洪林, 张新华, 石群立, 周晓军, 马捷. 胃肠道侵袭性 B 细胞淋巴瘤临床病理学研究. 中华病理学杂志. 2014:8-14. View at Publisher | View at Google Scholar | View at Indexing
  • Antognini AB, Giovagnoli A (2015) Adaptive designs for sequential treatment allocation. CRC Press; 2015 Apr 6. View at Publisher | View at Google Scholar | View at Indexing
  • Sverdlov O (2015) An Overview of Adaptive Randomization Designs in Clinical Trials. InModern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects 30: 3-44. View at Publisher | View at Google Scholar | View at Indexing
  • 周军, 马捷. c-myc 基因在侵袭性 B 细胞淋巴瘤中的研究进展. 中华病理学杂志. 2013;42:786-788. View at Publisher | View at Google Scholar | View at Indexing
  • Zhang LX (2015) Response–Adaptive Randomization: An Overview of Designs and Asymptotic Theory. InModern Adaptive Randomized Clinical Trials: Statistical and Practical 30: 221-249.

    View at Publisher | View at Google Scholar
  • Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A. Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: a TITE-CRM phase I/II clinical trial. Translational oncology. 2016 Apr 30;9(2):108-13.

    View at Publisher | View at Google Scholar
  • Banwell BL (2016) UNIVERSITY OF PENNSYLVANIA-PERELMAN SCHOOL OF MEDICINE.

    View at Publisher | View at Google Scholar
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The lancet oncology;13:1011-9.

    View at Publisher | View at Google Scholar
  • Graham R, McCoy MA, Schultz AM (2015)Resuscitation Research and Continuous Quality Improvement. Washington (DC): National Academies Press (US). View at Publisher | View at Google Scholar | View at Indexing
  • Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F.,et al. (2012) Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clinical Cancer Research ;18:4570-79.

    View at Publisher | View at Google Scholar
  • Yushan Shan, Zhang Lele, Zhang Haiying, Hu Xiaoguang, Zhang Weixi, et al. (2013) The value of enzyme-linked immunospot assay in the diagnosis of tuberculosis in children. Journal of Medical Research 42 : 151-4. View at Publisher | View at Google Scholar | View at Indexing
  • Camidge DR, Doebele RC. (2012)Treating ALK-positive lung cancer—early successes and future challenges. Nature reviews Clinical oncology ;9:268-277.

    View at Publisher | View at Google Scholar
  • Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Dilling TJ.(2015) Non–small cell lung cancer, version 6. Journal of the National Comprehensive Cancer Network ;13:515-524.

    View at Publisher | View at Google Scholar
  • Blanco E, Hargrave D (2014)Can we improve the efficiency of early phase trials in pediatric oncology?. Clinical Investigation 4: 1021-30.

    View at Publisher | View at Google Scholar
  • Atherly AJ, Camidge DR. (2015)The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British journal of cancer;106:1100-6.

    View at Publisher | View at Google Scholar
  • Kaddar M, Milstien J, Schmitt S (2014) Impact of BRICS? investment in vaccine development on the global vaccine market. Bulletin of the World Health Organization 92:436-46.

    View at Publisher | View at Google Scholar
  • Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer treatment reviews ;40:300-306.

    View at Publisher | View at Google Scholar
  • Herter-Sprie GS, Kung AL, Wong KK (2013) New cast for a new era: preclinical cancer drug development revisited. The Journal of clinical investigation 123: 3639-45. View at Publisher | View at Google Scholar | View at Indexing
  • Aisner DL, Marshall CB.(2012) Molecular Pathology of Non–Small Cell Lung Cancer. American journal of clinical pathology;138:332-346.

    View at Publisher | View at Google Scholar
  • Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A,et al. (2015) Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148:355-66.

    View at Publisher | View at Google Scholar
  • Weickhardt AJ, Rothman MS, Salian‐Mehta S, Kiseljak‐Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. (2012) Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer;118:5302-2309.

    View at Publisher | View at Google Scholar
  • Mangion IK, Chen CY, Li H, Maligres P, Chen Y, et al. (2014) Enantioselective Synthesis of an HCV NS5a Antagonist. Organic letters 16:2310-3.

    View at Publisher | View at Google Scholar
  • Pol S, Corouge M, Sogni P (2013) Oral antiviral therapies for chronic hepatitis C infection. Therapeutic advances in infectious disease 1:107-16. View at Publisher | View at Google Scholar | View at Indexing
  • O'Bryant CL, Wenger SD, Kim M, Thompson LA. (2013)Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Annals of Pharmacotherapy:189-197.

    View at Publisher | View at Google Scholar
  • Guedj J, Dahari H, Uprichard SL, Perelson AS (2013) The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert review of gastroenterology & hepatology 7:397-9. View at Publisher | View at Google Scholar | View at Indexing
  • Cagle PT, Zhai QJ, Murphy L, Low PS. (2013)Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Archives of pathology & laboratory medicine;137:241-244.

    View at Publisher | View at Google Scholar
  • Zhou N, Hernandez D, Ueland J, Yang X, Yu F, et al. (2016) NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. Journal of Infectious Diseases 213:206-15.

    View at Publisher | View at Google Scholar
  • Guedj J, Dahari H, Uprichard SL, Perelson AS (2013) The rapid viral decline with the HCV NS5A inhibitor daclatasvir reveals a dual mode of action and leads to a new HCV half-life estimate. Expert review of gastroenterology & hepatology 7:397. View at Publisher | View at Google Scholar | View at Indexing
  • Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J. (2013) Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer ;119:2383-2390.

    View at Publisher | View at Google Scholar
  • Salvatierra KA (2014) Resistencia a nuevos antivirales de acción directa en aislados clínicos del virus de la hepatitis C. View at Publisher | View at Google Scholar | View at Indexing
  • Sun H, Li Y, Li D, Hou T. (2013) Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches. Journal of chemical information and modeling ;53:2376-2389.

    View at Publisher | View at Google Scholar
  • Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, et al. (2016) Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. Journal of Antimicrobial Chemotherapy 71: 3495-3505. View at Publisher | View at Google Scholar | View at Indexing
  • O’Boyle, Donald R., and Min Gao. "NS5A as a Target for HCV Drug Discovery." HCV: The Journey from Discovery to a Cure (2019): 3-25. View at Publisher | View at Google Scholar | View at Indexing
  • Vijayvergia N, Mehra R.(2014) Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology;74:437-446.

    View at Publisher | View at Google Scholar
  • Goździk-Spychalska J, Szyszka-Barth K, Spychalski Ł, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R.(2014) C-MET inhibitors in the treatment of lung cancer. Current treatment options in oncology ;15:670-682.

    View at Publisher | View at Google Scholar
  • Eng L, Qiu X, Su J, Pringle D, Niu C, et al. (2015) The role of second‐hand smoke exposure on smoking cessation in non–tobacco‐related cancers. Cancer 121: 2655-63.

    View at Publisher | View at Google Scholar
  • Weickhardt, Andrew J., et al. "Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients." Cancer 119.13 (2013): 2383-2390. View at Publisher | View at Google Scholar | View at Indexing
  • Natoli S, Lazzari M, Dauri M (2015) Open questions in the treatment of cancer pain: time for a strong evidence-based approach?. View at Publisher | View at Google Scholar | View at Indexing
  • Sun, Huiyong, et al. "Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches." Journal of chemical information and modeling 53.9 (2013): 2376-2389. View at Publisher | View at Google Scholar | View at Indexing
  • FEBS J (2011) Bibliografía completa. FEBS J 278: 4649-67.

    View at Publisher | View at Google Scholar
  • Cagle, Philip T., et al. "Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents." Archives of pathology & laboratory medicine 137.2 (2013): 241-244. View at Publisher | View at Google Scholar | View at Indexing
  • Dodgen AL, Hill KD (2015) Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. Drug, healthcare and patient safety 7:175. View at Publisher | View at Google Scholar | View at Indexing
  • Weickhardt, Andrew J., et al. "Rapid?onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer." Cancer 118.21 (2012): 5302-5309. View at Publisher | View at Google Scholar | View at Indexing
  • Atherly, A. J., and D. R. Camidge. "The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers." British journal of cancer 106.6 (2012): 1100-1106. View at Publisher | View at Google Scholar | View at Indexing
  • Hill KD, Henderson HT, Hornik CP, Li JS (2015) Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials. gov and the Food and Drug Administration Pediatric Drug Labeling Database. Cardiology in the young 25:172-80. View at Publisher | View at Google Scholar | View at Indexing
  • Aisner, Dara L., and Carrie B. Marshall. "Molecular pathology of non–small cell lung cancer: a practical guide." American journal of clinical pathology 138.3 (2012): 332-346. View at Publisher | View at Google Scholar | View at Indexing

Relevant Topics